BioMarin Pharmaceutical Focuses on Rare Genetic Disorder Therapies

By Bobby Samwell • Monday, February 26 16:20 • Permanent Link

BioMarin Pharmaceutical has recently released its 10-K report, showcasing its focus on developing and commercializing therapies for individuals with rare genetic disorders. The company's commercial products include Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme. In 2023, the company achieved $2.4 billion in total revenues, with a net income of $167.6 million, marking a significant improvement from the previous year's loss of $64.1 million.

The company's Net Product Revenues for 2023 totaled $2,372.5 million, showing a substantial increase from the previous year's $2,042.0 million. This growth was primarily driven by higher sales volumes of several key products, including VOXZOGO, PALYNZIQ, and VIMIZIM. However, the sales of KUVAN experienced a decline due to increasing generic competition as a result of the loss of exclusivity in the U.S. in October 2020.

BioMarin Pharmaceutical also faced exposure to foreign currency exchange rates, with an unfavorable impact of $100.0 million driven by the Argentine Peso, Euro, Japanese Yen, and Russian Ruble. The company uses foreign currency exchange forward contracts to hedge a percentage of its foreign currency exposure, primarily the Euro.

In terms of research and development (R&D) expenses, the company saw a total R&D expense of $746.8 million in 2023, a significant increase from the previous year's $649.6 million. This rise was attributed to higher spending in research and early pipeline activities, including studies for planned clinical trial application submissions in the U.S. and EU.

BioMarin Pharmaceutical's gross margin for 2023 increased to 78.7% compared to 76.9% in 2022, primarily due to higher sales volume of products with higher margins, particularly related to VOXZOGO, and lower per unit manufacturing costs for its enzyme products.

The company also experienced a decrease in Royalty and Other Revenues in 2023, totaling $46.7 million, primarily due to lower royalty revenues earned from third parties. However, BioMarin Pharmaceutical expects to continue earning royalties from third parties in the future.

Following these announcements, the company's shares moved -1.2%, and are now trading at a price of $90.1. If you want to know more, read the company's complete 10-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.